How is the histological subtype of the ovarian carcinoma associated with hypoxia-related factors in terms of its chemotherapeutic resistance
| Project/Area Number |
18K06997
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
矢野 光剛 大分大学, 医学部, 助教 (70817064)
長谷川 幸清 埼玉医科大学, 医学部, 教授 (30534193)
宮澤 昌樹 東海大学, 医学部, 客員講師 (30624572)
宮澤 麻里子 東海大学, 医学部, 特定研究員 (80637091)
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 卵巣明細胞癌（OVCCC） / 高異型度漿液性癌 / 低酸素誘導因子（HIF） / ヒストン脱アセチル化酵素（HDAC） / ARID1A / Silibinin / 卵巣癌 / 低酸素 / HIF-1α / ヒストン脱アセチル化酵素 / 卵巣明細胞癌 / 卵巣漿液性癌 / 低酸素誘導因子 / PD-L1 / silibinin |
|---|
| Outline of Final Research Achievements |
In ovarian clear cell carcinomas (OVCCC), the single-nucleotide polymorphism (C1772T) of hypoxia inducible factor (HIF)-1α is more frequent than in healthy population as well as other carcinomas, but the single-nucleotide polymorphism does not affect its protein expression and the prognosis. Immunohistochemical expression of HIF-1α and its regulator histone deacetylase (HDAC) 6 do not correlate with prognosis in OVCCC patients without ARID1A mutation, but with ARID1A mutation significantly reduced survival time. It was supposed that in OVCCC HIF-1α and HDAC6 could be prognostic factors and therapeutic targets along with ARID1A as a biomarker.
Following these summaries shown in the report 15K08355, ///
|
| Academic Significance and Societal Importance of the Research Achievements |
我々の一連の研究においては，「卵巣明細胞癌（OVCCC）の低酸素関連因子の発現」に着目し，化学療法抵抗性との関わりから有望とされる標的因子の解明に取り組んできた。卵巣癌の薬物治療においては，昨今，BRCA遺伝子異常をもつ高異型度漿液性癌に対してのpoly-ADP ribose polymerase（PARP）阻害薬の意義が最も大きな話題となっているが，免疫チェックポイント阻害薬なども明細胞癌には有効性があまり注目されていないのが実情である。治療の個別化は今やいずれの悪性腫瘍においても必須の概念であり，がんパネル検査から発掘される新治療薬とも並行して，社会的なニーズに応えていく必要がある。
|
Report
(6 results)
Research Products
(14 results)
-
-
[Journal Article] Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy.2023
Author(s)
Yagishita S, Nishikawa T, Yoshida H, Shintani D, Sato S, Miwa M, Suzuki M, Yasuda M, Ogitani Y, Jikoh T, Yonemori K, Hasegawa K, Hamada A.
-
Journal Title
Clin Cancer Res.
Volume: CCR-22
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Diagnostic utility of a conventional MRI-based analysis and texture analysis for discriminating between ovarian thecoma-fibroma groups and ovarian granulosa cell tumors.2022
Author(s)
Nagawa K, Kishigami T, Yokoyama F, Murakami S, Yasugi T, Takaki Y, Inoue K, Tsuchihashi S, Seki S, Okada Y, Baba Y, Hasegawa K, Yasuda M, Kozawa E.
-
Journal Title
J Ovarian Res.
Volume: 15
Issue: 1
Pages: 65-65
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).2022
Author(s)
Yano M, Nasu K, Yasuda M, Katoh T, Kagabu M, Kobara H, Matsuura M, Tokuyama O, Yamawaki T, Wakahashi S, Noguchi T, Mizuno K, Shitsukawa K, Onohara Y, Nakabori T, Miyasaka A, Nakao T, Matsunaga T, Kunimi Y, Sakurai M, Uchiyama A, Itoh R, Ohike N, Hirakawa T, Watanabe T, Nishino K, Motohashi T, Ito K.
-
Journal Title
Melanoma Res.
Volume: 32
Issue: 3
Pages: 150-158
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
